ISORAY INC (ISR)       0.3254  +0.03 (+8.72%)

Company Profile

IsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The company is headquartered in Richland, Washington and currently employs 66 full-time employees. The company went IPO on 2002-05-31. The Company, through its subsidiary, Isoray Medical, Inc., develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The firm is engaged in production and sale of Cesium-131 brachytherapy seeds. Brachytherapy seeds are small devices that deliver a personalized targeted therapeutic dose of radiation used in an interstitial radiation procedure. The brachytherapy procedure places radioactive seeds as close as possible to (in or near) the cancerous tumor. The Cesium-131 includes radioisotope in the treatment of all malignant tumors, such as prostate cancer, brain cancer, colorectal cancer, gynecological cancer, lung cancer, ocular melanoma and pancreatic cancer. The Company’s Cesium-131 is classified as a Class II device.

Company Info

ISORAY INC

350 Hills Street, Suite 106

Richland WASHINGTON 99354

P: 15093751202.0

CEO: Lori A. Woods

Employees: 66

Website: https://isoray.com/